- Home
- AFRI vs FENC Comparison
AFRI vs FENC Comparison
Compare AFRI & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFRI
- FENC
- Stock Information
- Founded
- AFRI 1943
- FENC 1996
- Country
- AFRI Gibraltar
- FENC United States
- Employees
- AFRI N/A
- FENC N/A
- Industry
- AFRI Packaged Foods
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AFRI Consumer Staples
- FENC Health Care
- Exchange
- AFRI Nasdaq
- FENC Nasdaq
- Market Cap
- AFRI 207.7M
- FENC 225.4M
- IPO Year
- AFRI N/A
- FENC 2001
- Fundamental
- Price
- AFRI $7.89
- FENC $8.36
- Analyst Decision
- AFRI
- FENC Strong Buy
- Analyst Count
- AFRI 0
- FENC 2
- Target Price
- AFRI N/A
- FENC $13.50
- AVG Volume (30 Days)
- AFRI 10.7K
- FENC 56.4K
- Earning Date
- AFRI 08-22-2025
- FENC 08-14-2025
- Dividend Yield
- AFRI N/A
- FENC N/A
- EPS Growth
- AFRI N/A
- FENC N/A
- EPS
- AFRI N/A
- FENC N/A
- Revenue
- AFRI $274,223,000.00
- FENC $33,302,000.00
- Revenue This Year
- AFRI N/A
- FENC $0.85
- Revenue Next Year
- AFRI N/A
- FENC $55.16
- P/E Ratio
- AFRI N/A
- FENC N/A
- Revenue Growth
- AFRI N/A
- FENC N/A
- 52 Week Low
- AFRI $7.47
- FENC $3.96
- 52 Week High
- AFRI $11.80
- FENC $9.42
- Technical
- Relative Strength Index (RSI)
- AFRI 58.04
- FENC 48.45
- Support Level
- AFRI $7.70
- FENC $7.17
- Resistance Level
- AFRI $8.06
- FENC $9.42
- Average True Range (ATR)
- AFRI 0.20
- FENC 0.54
- MACD
- AFRI 0.02
- FENC 0.02
- Stochastic Oscillator
- AFRI 71.19
- FENC 52.89
About AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.